AR010139A1 - Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u - Google Patents
Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de uInfo
- Publication number
- AR010139A1 AR010139A1 ARP980101481A ARP980101481A AR010139A1 AR 010139 A1 AR010139 A1 AR 010139A1 AR P980101481 A ARP980101481 A AR P980101481A AR P980101481 A ARP980101481 A AR P980101481A AR 010139 A1 AR010139 A1 AR 010139A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecula
- antigen
- dna
- fas
- epitope
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una molécula que tiene una region de union de antígeno específica para un epítope del antígeno Fas, dicho epítope se conserva entre un primate y unanimal no primate; el uso de dicha molécula para la preparacion de un medicamento, un anticuerpo, ADN que codifica cualquier porcion individual delpolipéptido de dicha molécula, un vector de ADN recombinante, una célula huésped, E-coli, un método para producir un anticuerpo anti-Fas humanizado y unagente para el tratamiento de condiciones atribuibles a anormalidades en el sistema Fas/ligando de Fas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8295397 | 1997-04-01 | ||
JP16908897 | 1997-06-25 | ||
JP27606497 | 1997-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR010139A1 true AR010139A1 (es) | 2000-05-17 |
Family
ID=27304060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980101481A AR010139A1 (es) | 1997-04-01 | 1998-04-01 | Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0909816A1 (es) |
KR (1) | KR19980080993A (es) |
CN (1) | CN1207395A (es) |
AR (1) | AR010139A1 (es) |
AU (1) | AU734758B2 (es) |
BR (1) | BR9803296A (es) |
CA (1) | CA2233783A1 (es) |
CZ (1) | CZ294340B6 (es) |
HU (1) | HUP9800744A3 (es) |
ID (1) | ID20117A (es) |
IL (1) | IL123888A0 (es) |
NO (1) | NO981454L (es) |
NZ (1) | NZ330095A (es) |
PL (1) | PL325667A1 (es) |
RU (1) | RU2212412C2 (es) |
TR (1) | TR199800604A2 (es) |
TW (1) | TW526205B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
ATE553129T1 (de) * | 1998-01-23 | 2012-04-15 | Hoffmann La Roche | Antikörper gegen humanes il-12 |
AU4772299A (en) * | 1998-06-18 | 2000-01-05 | Karolinska Innovations Ab | Fas peptides and antibodies for modulating apoptosis |
AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
NZ515598A (en) * | 1999-05-24 | 2004-05-28 | Sankyo Co | Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US20070129291A1 (en) * | 2001-08-01 | 2007-06-07 | Genset S.A. | Genobix agonists and antagonists for use in the treatment of metabolic disorders |
EP2383290B1 (en) | 2001-08-23 | 2019-05-08 | Rsr Limited | Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto |
ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
TR201815885T4 (tr) | 2004-01-07 | 2018-11-21 | Novartis Vaccines & Diagnostics Inc | M-csf spesifik monoklonal antikorlar ve bunların kullanımı. |
WO2010013498A1 (ja) * | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | 変形性関節症治療剤又は予防剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09503672A (ja) * | 1993-10-14 | 1997-04-15 | イミュネックス・コーポレーション | Fas拮抗剤とその利用 |
JPH09508009A (ja) * | 1994-01-07 | 1997-08-19 | イミュネックス・コーポレーション | Fas抗原を結合するリガンド |
AU6091496A (en) * | 1995-06-07 | 1996-12-30 | Chiron Corporation | Antibodies to fas antigen capable of inhibiting apoptosis |
GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
-
1998
- 1998-03-30 IL IL12388898A patent/IL123888A0/xx unknown
- 1998-03-30 AU AU59701/98A patent/AU734758B2/en not_active Ceased
- 1998-03-31 CA CA002233783A patent/CA2233783A1/en not_active Abandoned
- 1998-03-31 ID IDP980478A patent/ID20117A/id unknown
- 1998-03-31 NZ NZ330095A patent/NZ330095A/xx unknown
- 1998-03-31 TW TW087104806A patent/TW526205B/zh not_active IP Right Cessation
- 1998-03-31 NO NO981454A patent/NO981454L/no not_active Application Discontinuation
- 1998-03-31 RU RU98105631/13A patent/RU2212412C2/ru not_active IP Right Cessation
- 1998-04-01 CZ CZ1998985A patent/CZ294340B6/cs not_active IP Right Cessation
- 1998-04-01 HU HU9800744A patent/HUP9800744A3/hu unknown
- 1998-04-01 PL PL98325667A patent/PL325667A1/xx unknown
- 1998-04-01 CN CN98108265A patent/CN1207395A/zh active Pending
- 1998-04-01 EP EP98302575A patent/EP0909816A1/en not_active Withdrawn
- 1998-04-01 BR BR9803296-8A patent/BR9803296A/pt not_active IP Right Cessation
- 1998-04-01 TR TR1998/00604A patent/TR199800604A2/xx unknown
- 1998-04-01 AR ARP980101481A patent/AR010139A1/es unknown
- 1998-04-01 KR KR1019980011477A patent/KR19980080993A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2233783A1 (en) | 1998-10-01 |
BR9803296A (pt) | 2000-01-11 |
TR199800604A3 (tr) | 1999-10-21 |
PL325667A1 (en) | 1998-10-12 |
NZ330095A (en) | 1998-12-23 |
CZ98598A3 (cs) | 1998-10-14 |
NO981454L (no) | 1998-10-02 |
ID20117A (id) | 1998-10-01 |
CN1207395A (zh) | 1999-02-10 |
HU9800744D0 (en) | 1998-05-28 |
HUP9800744A2 (hu) | 1999-02-01 |
TR199800604A2 (xx) | 1999-10-21 |
IL123888A0 (en) | 1998-10-30 |
HUP9800744A3 (en) | 2001-04-28 |
AU734758B2 (en) | 2001-06-21 |
CZ294340B6 (cs) | 2004-12-15 |
NO981454D0 (no) | 1998-03-31 |
KR19980080993A (ko) | 1998-11-25 |
TW526205B (en) | 2003-04-01 |
RU2212412C2 (ru) | 2003-09-20 |
EP0909816A1 (en) | 1999-04-21 |
AU5970198A (en) | 1998-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012035A1 (es) | Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
AR010139A1 (es) | Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
NO953699D0 (no) | Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav | |
CY1108175T1 (el) | ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR | |
AR006250A1 (es) | Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico | |
CR6538A (es) | Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso | |
DE69129989D1 (de) | Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
CL2008003323A1 (es) | Uso de un anticuerpo que se une a cd20 porque sirve para preparar un medicamento para tratar enfermedades autoinmunes; acido nucleico que codifica una proteina cd20 de mono cynomolgus; vector que lo comprende; celula huesped y polipeptido cd20 de mono cynomolgus (div.sol.no.2639-03). | |
DE69535719D1 (de) | Fas-antigenbindender ligand | |
ES543938A0 (es) | Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis. | |
FI945221A0 (fi) | Yhdistelmä-DNA-molekyylejä, jotka koodittavat aminopeptidaasientsyymejä, ja niiden käyttö rokotteiden valmistamiseksi matotartuntoja vastaan | |
BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
UY27499A1 (es) | Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular | |
NO20010412L (no) | Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine | |
ATE296312T1 (de) | Metalkomplexbildner | |
DK0500659T3 (da) | Monoklonale antistoffer. | |
GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
ATE410514T1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
ATE490785T1 (de) | Parathormon-antikörper und damit zusammenhängende verfahren | |
NO980743L (no) | Antisekretoriske faktorpeptider som regulerer patologiske permeabilitetsforandringer | |
BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |